Proshares UltraShort Nasdaq Biotech

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Reverse Stock Split

合股

Ex Date: 2026.05.28 (EST), 1-for-2 Reverse Stock Split

588250

159849

159892

510660

159837

SBIO

LABU

ARKG

516500

512290

Kali Therapeutics announced that preclinical data for KT502, a novel CD19 x CD3 T-cell engager, will be presented at the EULAR 2026 Annual Congress in London. KT502 aims to provide deep B-cell depletion for autoimmune diseases with a favorable safety profile. The presentation is scheduled for June 4, 2026, highlighting its potential therapeutic benefits and the company's progress in expanding its clinical pipeline following the initiation of KT501.

prnewswire

Penghua SSE STAR Biology and Medicine ETF

Health Care Select Sector SPDR

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

China Merchants CSI Biotechnology Theme ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Invesco Biotechnology & Genome ETF

E Fund CSI Biotechnology Theme ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Ark Genomic Revolution ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

iShares Global Healthcare

Huaan Hang Seng Biotech ETF

First Trust NYSE Arca Biotech Index Fd

BlackRock, Inc.

07:01 ETKali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

588130

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Yinhua CSI Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua CSI HK Connect Health Care Composite ETF

iShares Biotechnology ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

VG Health

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Microbiotica reports positive results for MB097 in advanced melanoma

HBM Holdings Ltd. announced promising preclinical results for LET003, an AI-enabled monoclonal antibody targeting obesity. In animal models, LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, suggesting its potential as a leading obesity therapy. Analysts rate HBM stock as a Buy with a target price of HK$17.00, reflecting confidence in its innovative approach to obesity treatment.

Tip Ranks

HBM HOLDINGS-B

HBM Holdings Unveils Promising Preclinical Data for AI-Enabled Obesity Antibody LET003

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

Bosera Hang Seng SCHK Innovative Drug Select ETF

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News

StockTitan

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Invesco Pharmaceuticals ETF

Range Cancer Therapeutics

Tema Oncology ETF

Regulatory round-up: A month of key FDA approvals for cancer drugs

Ring Therapeutics®, a biotech firm based in Cambridge, Massachusetts, disclosed fresh insights on its Vector Conjugate system and VectorBricks™ in vitro manufacturing technology. The company unveiled this data on May 14, 2026. The innovative platform aims to develop precise medications.

Unusual Whales

Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference

The National Kidney Foundation (NKF) has invested in Biohope, a biotechnology firm focused on personalized medicine for kidney transplantation. This investment aims to support Biohope's clinical validation studies and regulatory approval for its Immunobiogram® platform, which tailors immunosuppressive therapy to individual patients. The technology seeks to reduce complications and improve graft survival for kidney transplant recipients, addressing the urgent need for personalized post-transplant care. NKF's Innovation Fund, launched in 2021, supports innovative kidney therapies to enhance patient outcomes.

Ping An CSI Medicine and Medical Device Innovation ETF

01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation

159929

SBP GROUPannounced preclinical data for its innovative drug TQF6422 at the 2026 European Congress on Obesity. TQF6422, a fully human monoclonal antibody targeting ActRII A/B, promotes muscle growth and fat reduction. Its in vitro activity exceeds comparable products by over 10 times. In combination with semaglutide, TQF6422 showed significant synergistic effects, increasing fat reduction by 1.5 to 2 times in an obese monkey model, with fat loss comprising 93% of total weight loss.

AASTOCKS News

China Universal 800 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai SSE STAR Brand Name Drug ETF

SBP GROUP

SBP GROUP  Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity

Fingerprint Cards AB reported a mixed Q1 earnings call, highlighting a 4% revenue growth and a 62.3% gross margin, despite challenges like negative EBITDA and tight cash. The company is banking on a merger with Precise Biometrics to address its subscale cost base, aiming for significant annual cost synergies. AllKey platform is emerging as a key growth driver, representing 75% of the Q1 pipeline. However, the company faces liquidity pressures and must successfully execute the merger to achieve sustainable profitability.

Fingerprint Cards AB Bets on Merger-Led Turnaround

Proshares UltraShort Nasdaq Biotech(BIS.US)

07:01 ETKali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

Microbiotica reports positive results for MB097 in advanced melanoma

HBM Holdings Unveils Promising Preclinical Data for AI-Enabled Obesity Antibody LET003

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News